Altogether, these data demonstrate that GSDMB overexpression is functionally involved in promoting resistance to the anti-HER2 inmunotherapy trastuzumab, and this may explain its association with adverse clinical behaviour in HER2+ cancers. Here, ERBB2 is linked to cancer.